Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Conclusions
GRACE met its primary endpoint
Significant improvements in hypertension, hyperglycemia, and other manifestations of cortisol excess were observed throughout the treatment with relacorilant
Due to relacorilant’s specificity for the glucocorticoid receptor and its unique mechanism of action, the observed efficacy was seen: Without cases of relacorilant-induced irregular vaginal bleeding with endometrial hypertrophy
Without increases in cortisol concentrations and relacorilant-induced hypokalemia
Without reported cases of adrenal insufficiency
Without independently-confirmed QT prolongation